Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants Jul 19, 2023 | Uncategorized
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting Jul 19, 2023 | Uncategorized
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells Jul 7, 2023 | Uncategorized
